Announcement PDF ASX Announcement Phase II Bisantrene trial data to be presented at ASH 2020  Phase II Bisantrene clinical trial data to be presented at the American Society for Haematology 2020 Annual Conference (ASH 2020)  All ASH presentations are selected by peer-review  ASH is the premier international conference for haematology 5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba Medical Centre has been accepted for presentation at the American Society for Haematology 2020 Conference (ASH 2020). This open label, single agent trial, led by Professor Arnon Nagler, studied patients (n=10) with relapsed or refractory Acute Myeloid Leukaemia (R/R AML) who on average had failed three prior lines of treatment. Bisantrene was found to be well tolerated, and after only a single course of treatment, had an overall clinical response rate of 40% (ASX Announcement: June 16 2020). The ASH Annual Meeting is the premier international clinical conference for malignant and nonmalignant haematology and attracts over 30,000 attendees across four days. The annual meeting presentations are chosen by peer-review and cover the latest developments in scientific and clinical research in the field of haematology. The presentation, entitled “A Phase II Study of Bisantrene in Patients with Relapsed/ Refractory Acute Myeloid Leukemia” will be presented on 5 December 2020. The abstract for this presentation is available via: ash.confex.com/ash/2020/webprogram/Paper135947.html - ENDS About Race Oncology (RAC: ASX) Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020. Release authorised by: Media contact: Phil Lynch, CEO/MD Jane Lowe, IR Department phillip.lynch@raceoncology.com + 61 411 117 774 jane.lowe@irdepartment.com.au Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com